RCUS stock news today

Leerink Partners keeps Outperform on Arcus Biosciences, lifts target to $49

Leerink Partners reiterated its Outperform rating on Arcus Biosciences and raised its price target to $49. The update reflects the analyst's view on the stock.

Truist Securities keeps Buy rating on Arcus Biosciences, cuts price target to $40

Truist Securities reiterated a Buy rating on Arcus Biosciences while reducing its price target to $40. The change reflects the firm's updated view on the stock.

Wedbush lowers Arcus Biosciences target to $45 from $49

Wedbush reduced its valuation estimate for Arcus Biosciences, now at $45 versus $49 before. The adjustment reflects the firm's revised outlook on the shares.

Wedbush keeps Outperform rating on Arcus Biosciences, cuts target to $45

Wedbush reiterated an Outperform rating on Arcus Biosciences while reducing its price target to $45. The change reflects the firm's updated view on the stock.

Arcus Biosciences posts Q3 2026 results, updates drug pipeline

The biotech company shared its quarterly financial figures for the three months ended in 2026 and gave an update on its drug development programs. No specific numbers appeared in the headline.

Arcus Biosciences posts wider quarterly loss but revenue tops estimates

The company reported a per-share loss of $1.00 for its latest quarter, missing the $0.90 loss analysts expected. Revenue of $9.000 million came in above the $8.305 million estimate.

Arcus Biosciences sets date for Q3 2026 earnings release

Arcus Biosciences will publish its quarterly results for the three months ended September 2026. The company announced when that disclosure will happen.

Arcus Biosciences Sets Terms for $250 Million Share Sale

The biotech company fixed the pricing of a stock sale worth $250 million. It plans to raise funds by issuing new shares.

Arcus Biosciences prices offering of 14,285,715 shares at $17.50 each

Arcus Biosciences set terms for a public offering of 14,285,715 common shares priced at $17.50 per share. The company expects about $250 million in gross proceeds from the sale.

Kuehn Law Opens Investigation Into Arcus Biosciences

Kuehn Law, PLLC said it is investigating Arcus Biosciences, Inc. The firm did not disclose what the probe concerns.

Arcus Biosciences begins public offering of common stock

Arcus Biosciences has launched a public offering of its common stock. The size of the offering was not disclosed.

Form 8-K tells shareholders about important events such as deals, leadership changes or results.

Citigroup keeps Buy rating on Arcus Biosciences, lifts target to $50

Citigroup reiterated its Buy rating on Arcus Biosciences and raised its price target to $50. The change reflects the analyst's updated view on the stock.

Truist Securities keeps Buy rating on Arcus Biosciences, lifts target to $41

Truist Securities reiterated its Buy rating on Arcus Biosciences and raised its price target to $41. The change reflects the firm's updated view on the stock.

Wedbush Keeps Outperform Rating on Arcus Biosciences, Lifts Target to $49

Wedbush reiterated its Outperform rating on Arcus Biosciences and raised its price target to $49. The update reflects the analyst's current view on the stock.

Wedbush lifts Arcus Biosciences target to $49, keeps Outperform

Wedbush raised its valuation estimate for Arcus Biosciences shares to $49 from $43. The firm maintained its Outperform rating on the stock.

Truist Financial raised its price target on Arcus Biosciences (RCUS) to $41 from $40.

Citigroup kept its Buy rating on Arcus Biosciences (RCUS) and raised its price target to $50 from $45.

Arcus Biosciences Reports New ARC-20 Trial Data for Casdatifan in Kidney Cancer

Arcus Biosciences released new findings from its ARC-20 study of casdatifan in kidney cancer. The data update covers an experimental treatment being tested in this cancer type.

Casdatifan data shows nearly 3-year median survival in pretreated kidney cancer, Arcus says

Arcus Biosciences disclosed results for casdatifan in patients with kidney cancer who had received extensive prior treatment, with median overall survival approaching three years. Phase 3 studies of the therapy have not yet begun.

William Blair Starts Arcus Biosciences Coverage With Outperform Rating

William Blair began covering Arcus Biosciences and assigned an Outperform rating to the stock. The rating reflects the firm's positive view of the company.

JP Morgan starts Arcus Biosciences coverage with Overweight rating, $41 price target

JP Morgan began covering Arcus Biosciences and gave the stock an Overweight rating. The firm set a price target of $41 per share.

Wedbush Keeps Outperform Rating on Arcus Biosciences, $43 Target Unchanged

An analyst at Wedbush repeated a positive rating for Arcus Biosciences and left the $43 price target as is.

TD Cowen Starts Arcus Biosciences Coverage With Buy Rating

TD Cowen began covering Arcus Biosciences and assigned a Buy rating to the stock. The rating reflects the firm's positive view on the company.

Truist Securities keeps Buy rating on Arcus Biosciences, lifts target to $40

Truist Securities repeated its Buy rating on Arcus Biosciences and increased its price target to $40. The move reflects the firm's updated view on the stock.

Form 4 reports shares bought or sold by company insiders such as officers, directors or large holders.

What is the latest news on RCUS?

Nov 5, 2026: Leerink Partners keeps Outperform on Arcus Biosciences, lifts target to $49 (Benzinga) · Nov 5, 2026: Truist Securities keeps Buy rating on Arcus Biosciences, cuts price target to $40 (Benzinga) · Nov 5, 2026: Wedbush lowers Arcus Biosciences target to $45 from $49 (Fiscal.ai)

What are analysts saying about RCUS?

Oct 21, 2026: Truist Financial raised its price target on Arcus Biosciences (RCUS) to $41 from $40. · Oct 21, 2026: Citigroup kept its Buy rating on Arcus Biosciences (RCUS) and raised its price target to $50 from $45.

What has RCUS filed with the SEC recently?

Oct 21, 2026: Arcus Biosciences, Inc. filed a report on a major company event (Form 8-K) · Aug 24, 2026: Arcus Biosciences, Inc. filed an insider trading report (Form 4)